Olaparib - AstraZeneca

Drug Profile

Olaparib - AstraZeneca

Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; Eli Lilly; European Network of Gynaecological Oncological Trial Groups; German Breast Group; M. D. Anderson Cancer Center; Mario Negri Institute for Pharmacological Research; Massachusetts General Hospital; Merck & Co; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Oxford; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Registered Fallopian tube cancer; Peritoneal cancer
  • Preregistration Breast cancer
  • Phase III Pancreatic cancer; Prostate cancer
  • Phase II Gastric cancer; Solid tumours
  • Phase I/II Glioblastoma; Head and neck cancer; Small cell lung cancer
  • Phase 0 Endometrial cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 14 Nov 2017 AstraZeneca plans a phase II study in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (NCT03330847)
  • 14 Nov 2017 AstraZeneca plans the phase II HUDSON trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Austria, Canada, Germany and South Korea, in November 2017 (NCT03334617)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Australia (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top